Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
| ▸ | CD44 | P16070 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20331679 | 0.64 | PNMT (0.31) | PNMTCD44MAOB | |
| SCHEMBL16603037 | 0.62 | — | — | |
| SCHEMBL952998 | 0.61 | — | — | |
| SCHEMBL23956373 | 0.58 | PNMT (0.34) | PNMTCD44MAOB | |
| SCHEMBL12209077 | 0.58 | — | — | |
| SCHEMBL23348760 | 0.58 | PNMT (0.32) | PNMTCD44MAOB | |
| SCHEMBL22488571 | 0.58 | — | — | |
| SCHEMBL22908212 | 0.58 | — | — | |
| SCHEMBL2115873 | 0.58 | — | — | |
| Hydrochloric Acid SCHEMBL29078103 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652180-B1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2023-09-21 | — | — | US | disclosed |
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | DART NEUROSCIENCE, LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC | 2023-05-11 | — | — | US | disclosed |
| EP-3759085-B1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE LLC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC | 2022-08-25 | — | — | US | disclosed |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | DART NEUROSCIENCE, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | DART NEUROSCIENCE, LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2019-06-13 | — | — | US | disclosed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2019014305-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685745-B2 | Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors | PDE7A, PDE7B, PDE8B | PNMT 1646/4885CD44 4872/4885MAOB 188/4885 |
| US-20210340127-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | PNMT 17/4885CD44 4343/4885MAOB 145/4885 |
| US-20230295178-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | PNMT 528/4885CD44 3604/4885MAOB 320/4885 |
| US-11365191-B2 | Substituted cyclohexyl compounds as NOP inhibiiors | OPRL1, OPRK1, GAP43 | PNMT 96/4885CD44 3870/4885MAOB 199/4885 |
| US-20230144411-A1 | SUBSTITUTED CYCLOHEXYL COMPOUNDS AS NOP INHIBITORS | OPRL1, OPRK1, NOP56 | PNMT 17/4885CD44 4343/4885MAOB 145/4885 |
| US-20190177327-A1 | SUBSTITUTED METHYL PYRAZOLOPYRIMIDINONE AND METHYL IMIDAZOPYRAZINONE COMPOUNDS AS PDE1 INHIBITORS | PDE3A, PDE5A, PDE4A | PNMT 260/4885CD44 4328/4885MAOB 1062/4885 |
| US-20220267351-A1 | SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS | PDE7A, PDE7B, PDE8B | PNMT 1646/4885CD44 4872/4885MAOB 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.